US45720N1037
US45720N1037
Inhibrx Biosciences, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 1.300.000 | 200.000 | 550.0% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 136.325.000 | 331.648.000 | 58.9% | |
| Operating Income | -135.025.000 | -331.448.000 | 59.3% |
| Pretax Income | -140.053.000 | 1.687.574.000 | 108.3% |
| Net Income Common Stockholders | -140.055.000 | 1.687.572.000 | 108.3% |
| -- | -- | -- | |
| -- | -- | -- |